Rhumbline Advisers Increases Holdings in Tricida, Inc. (NASDAQ:TCDA)


Share on StockTwits

Rhumbline Advisers boosted its stake in shares of Tricida, Inc. (NASDAQ:TCDA) by 9.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 38,600 shares of the company’s stock after buying an additional 3,470 shares during the quarter. Rhumbline Advisers owned approximately 0.08% of Tricida worth $272,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. ProShare Advisors LLC raised its position in Tricida by 21.4% in the fourth quarter. ProShare Advisors LLC now owns 14,008 shares of the company’s stock worth $99,000 after acquiring an additional 2,473 shares during the period. Wells Fargo & Company MN grew its holdings in Tricida by 84.2% during the fourth quarter. Wells Fargo & Company MN now owns 23,381 shares of the company’s stock valued at $164,000 after purchasing an additional 10,688 shares during the period. Teachers Retirement System of The State of Kentucky increased its position in Tricida by 10.6% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 24,764 shares of the company’s stock worth $224,000 after buying an additional 2,364 shares during the last quarter. ExodusPoint Capital Management LP bought a new stake in shares of Tricida in the third quarter valued at $262,000. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Tricida by 54.1% in the third quarter. UBS Asset Management Americas Inc. now owns 30,500 shares of the company’s stock valued at $276,000 after buying an additional 10,709 shares during the period. Institutional investors and hedge funds own 70.46% of the company’s stock.

In related news, CEO Gerrit Klaerner sold 16,690 shares of the business’s stock in a transaction dated Thursday, January 14th. The stock was sold at an average price of $7.39, for a total transaction of $123,339.10. Following the completion of the transaction, the chief executive officer now directly owns 509,648 shares in the company, valued at $3,766,298.72. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Sandra I. Coufal sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 3rd. The stock was sold at an average price of $6.91, for a total value of $34,550.00. Following the completion of the transaction, the director now owns 162,609 shares in the company, valued at $1,123,628.19. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,179 shares of company stock worth $378,092. Insiders own 70.40% of the company’s stock.

Separately, Zacks Investment Research cut Tricida from a “hold” rating to a “sell” rating in a research note on Wednesday, February 10th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $22.00.

Shares of NASDAQ TCDA opened at $5.11 on Thursday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 7.00 and a current ratio of 7.00. Tricida, Inc. has a fifty-two week low of $3.74 and a fifty-two week high of $32.99. The stock has a market cap of $256.75 million, a PE ratio of -0.95 and a beta of 1.40. The stock has a fifty day moving average of $5.43 and a 200-day moving average of $7.11.

Tricida (NASDAQ:TCDA) last issued its earnings results on Thursday, February 25th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.05). On average, sell-side analysts predict that Tricida, Inc. will post -5.24 EPS for the current year.

Tricida Company Profile

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Read More: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding TCDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tricida, Inc. (NASDAQ:TCDA).

Institutional Ownership by Quarter for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.